Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A D Thor

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Journal of the National Cancer Institute|July 5, 1995
Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinomaK Axelsson, B M Ljung, D H Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2000
HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancerA Stark, B S Hulka, S Joens, et al.
The New England Journal of Medicine|May 5, 1994
c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancerH B Muss, A D Thor, D A Berry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancerD A Berry, H B Muss, A D Thor, et al.
Journal of the National Cancer Institute|June 3, 1992
Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancersA D Thor, I I Moore DH, S M Edgerton, et al.
Journal of Neuropathology and Experimental Neurology|January 1, 1993
Comparative study of p53 gene and protein alterations in human astrocytic tumorsD N Louis, A von Deimling, R Y Chung, et al.
Cancer Research|December 15, 1989
Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-upA D Thor, L H Schwartz, F C Koerner, et al.
Journal of the National Cancer Institute|September 25, 1998
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancerA D Thor, D A Berry, D R Budman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trialK L Tedesco, A D Thor, D H Johnson, et al.
Archives of Pathology & Laboratory Medicine|July 11, 2000
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999P L Fitzgibbons, D L Page, D Weaver, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Journal of the National Cancer Institute|July 5, 1995
Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinomaK Axelsson, B M Ljung, D H Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2000
HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancerA Stark, B S Hulka, S Joens, et al.
The New England Journal of Medicine|May 5, 1994
c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancerH B Muss, A D Thor, D A Berry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancerD A Berry, H B Muss, A D Thor, et al.
Journal of the National Cancer Institute|June 3, 1992
Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancersA D Thor, I I Moore DH, S M Edgerton, et al.
Journal of Neuropathology and Experimental Neurology|January 1, 1993
Comparative study of p53 gene and protein alterations in human astrocytic tumorsD N Louis, A von Deimling, R Y Chung, et al.
Cancer Research|December 15, 1989
Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-upA D Thor, L H Schwartz, F C Koerner, et al.
Journal of the National Cancer Institute|September 25, 1998
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancerA D Thor, D A Berry, D R Budman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trialK L Tedesco, A D Thor, D H Johnson, et al.
Archives of Pathology & Laboratory Medicine|July 11, 2000
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999P L Fitzgibbons, D L Page, D Weaver, et al.
Pageof 5